This company is a contract development and manufacturing organization (CDMO) and contract manufacturer serving the pharmaceutical and biotech industry with a focus on peptide-based drugs and delivery systems. Their facility is a GMP-certified clean-room manufacturing site where they develop and produce various pharmaceutical products on behalf of clients.
The company manufactures peptide APIs (Active Pharmaceutical Ingredients) such as tirzepatide and semaglutide used in diabetes and weight-loss medicines. They develop and produces finished drug products in multiple forms, including: Sterile injectables (e.g., tirzepatide, semaglutide), Oral tablets and capsules, Transdermal patches (e.g., for smoking cessation), Bulk peptide batches for research, clinical use, and commercial supply.

They also offer private-label and contract manufacturing services for other peptide and self-care products.
They provide analytical, formulation, regulatory support, and packaging services to help partners bring products from development through commercialization.

This company represents a rare and highly attractive opportunity for a prospective buyer to step into a rapidly expanding sector with massive upside potential. With strong industry demand, established infrastructure, and an operational foundation already in place, a new owner can immediately leverage existing capabilities while scaling production, expanding customer relationships, and capturing additional market share. The business sits at the center of a growth trend driven by increasing reliance on outsourced pharmaceutical manufacturing and high-demand peptide therapeutics, positioning a buyer to benefit from continued market expansion, recurring revenue potential, and long-term value creation.

The target buyer will be a strategic in the industry with their own location in North Texas. Seller will finance the movement of the equipment and set up as well as training any new employees that are needed.